Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: A retrospective European group for blood and marrow transplantation analysis

Journal of Clinical Oncology

Volumn 26, Issue 31, 2008, Pages 5094-5100

  Schetelig, Johannes ^a   Van Biezen, Anja ^b   Brand, Ronald ^b   Caballero, Dolores ^b   Martino, Rodrigo ^b   Itala, Maija ^b   García Marco, José A ^b   Volin, Liisa ^b   Schmitz, Norbert ^b   Schwerdtfeger, Rainer ^b   Ganser, Arnold ^b   Onida, Francesco ^b   Mohr, Brigitte ^b   Stilgenbauer, Stephan ^b   Bornhäuser, Martin ^b   De Witte, Theo ^b   Dreger, Peter ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ATG FRESENIUS; ATG GENZYME; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DATA ANALYSIS; DATA BASE; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; REMISSION; RETROSPECTIVE STUDY; SIBLING; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; QUESTIONNAIRES; REGISTRIES; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 55549097826     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.2982     Document Type: Article

References (30)

1. Vousden KH, Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283, 2007
2. Rosenwald A, Chuang EY, Davis RE, et al: Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104:1428-1434, 2004
3. Döhner H, Fischer K, Bentz M, et al: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589, 1995
4. Stilgenbauer S, Kröber A, Busch R, et al: 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: First analysis of genetics in the CLL4 trial of the GCLLSG. Blood 106:212a, 2005 (abstr 715)
5. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000
6. Oscier D, Wade R, Orchard JA, et al: Prognostic factors in the UK LRF CLL4 trial. Blood 108:92a, 2006 (abstr. 299)
7. Lozanski G, Heerema NA, Flinn IW, et al: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281, 2004
8. Sayala HA, Moreton P, Jones RA, et al: Final report of the UKCLL02 trial: A phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL. Blood 108:14a, 2006 (abstr 34)
9. Stilgenbauer S, Winkler D, Kröber A, et al: Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG). Blood 110:918a, 2007 (abstr 3120)
10. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007
11. Dreger P, Corradini P, Kimby E, et al: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia 21:12-17, 2007
12. Hallek M, Cheson B, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute Working Group (NCI-WG) 1996 guidelines. Blood 111:5446-5456, 2008
13. Schetelig J, Thiede C, Bornhauser M, et al: Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group. J Clin Oncol 21:2747-2753, 2003
14. Sorror ML, Maris MB, Sandmaier BM, et al: Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23:3819-3829, 2005
15. Delgado J, Thomson K, Russell N, et al: Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: A British Society of Blood and Marrow Transplantation Study. Blood 107:1724-1730, 2006
16. Michallet M, Michallet AS, Le QH, et al: Conventional HLA-identical sibling bone marrow transplantation is able to cure chronic lymphocytic leukemia: A study from the EBMT and IBMT registries. Blood 102:474a, 2003 (abstr 1729)
17. Pavletic SZ, Khouri IF, Haagenson M, et al: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: Results from the Center for International Blood and Marrow Transplant research. J Clin Oncol 23:5788-5794, 2005
18. Moreno C, Villamor N, Colomer D, et al: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23:3433-3438, 2005
19. Caballero D, Garcia-Marco JA, Martino R, et al: Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res 11:7757-7763, 2005
20. Brown JR, Kim HT, Li S, et al: Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 12:1056-1064, 2006
21. Khouri IF, Saliba RM, Admirand J, et al: Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137:355-363, 2007
22. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
23. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
24. Gray R: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
25. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomised controlled trial. Lancet 370:230-239, 2007
26. Dreger P, Brand R, Milligan D, et al: Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: A population-matched analysis. Leukemia 19:1029-1033, 2005
27. Sorror M, Storer B, Sandmaier BM, et al: Long-term follow up of patients with high-risk chronic lymphocytic leukemia given nonmyeloablative allogeneic hematopoietic cell transplantation. Blood 110:496a, 2007 (abstr 1662)
28. Ritgen M, Stilgenbauer S, Von Neuhoff N, et al: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy chain gene status: Implications of minimal residual disease measurement with quantitative PCR. Blood 104:2600-2602, 2004
29. Montserrat E, Moreno C, Esteve J, et al: How I treat refractory CLL. Blood 107:1276-1283, 2006
30. Best G, Gardiner A, Davis ZA, et al: A subset of CLL patients with TP53 abnormalities and mutated VH genes have stable disease. Leuk Lymphoma 48:S80-S81, 2007 (suppl)